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Abstract
The cell cycle system is controlled in a timely manner by three groups of cyclins, cyclin dependent kinases and cyclin
dependent kinase inhibitors. Abnormal alterations of cell cycle regulatory mechanisms are a common feature of many
diseases including numerous tumor types such as ovarian cancer. Although a variety of cell cycle regulatory genes are well
known in mammalian species including human and mice, they are not well studied in avian species, especially in laying hens
which are recognized as an excellent animal model for research relevant to human ovarian carcinogenesis. Therefore, in the
present study, we focused on comparative expression and regulation of expression of candidate genes which might be
involved in the cell cycle program in surface epithelial ovarian cancer in laying hens. Our current results indicate that
expression levels of cell cycle gene transcripts are greater in cancerous as compared to normal ovaries. In particular, cyclin
A2 (CCNA2), CCND1, CCND2, CCND3, CCNE2, cyclin dependent kinase 1 (CDK1), CDK3, CDK5, cyclin dependent kinases
inhibitor 1A (CDKN1A) and CDKN1B were upregulated predominantly in the glandular epithelia of cancerous ovaries from
laying hens. Further, several microRNAs (miRs), specifically miR-1798, miR-1699, miR-223 and miR-1744 were discovered to
influence expression of CCND1, CCNE2, CDK1, and CDK3 mRNAs, respectively, via their 39-UTR which suggests that post-
transcriptional regulation of gene expression influences their expression in laying hens. Moreover, miR-1626 influenced
CDKN1A expression and miR-222, miR-1787 and miR-1812 regulated CDKN1B expression via their 39-UTR regions.
Collectively, results of the present study demonstrate increased expression of cell cycle-related genes in cancerous ovaries
of laying hens and indicate that expression of these genes is post-transcriptionally regulated by specific microRNAs.
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Introduction
Epithelial ovarian cancer (EOC), the most lethal gynecological
malignancy, claims the lives of over 15,000 women and 22,000 are
diagnosed with the disease in the US each year [1]. However, over
75% of woman diagnosed are at an advanced stage of EOC,
because it is generally asymptomatic and there is no specific
biomarker(s) for early detection [2]. Therefore, to prevent and
cure this lethal disease and to improve the long-term survival of
patients with EOC, the most promising approach is to identify
markers for early diagnosis. To overcome the problem that EOC
is rarely detected at an early stage, many animal models have been
developed, but they have not proven to be successful. For instance,
genetically manipulated rodent models have been used to elucidate
some aspects of the pathogenesis and etiologies of EOC; however,
the non-spontaneous nature of their ovarian cancer limits their
clinical relevance [3,4,5]. In fact, the laying hen is the only animal
that spontaneously develops ovarian cancer of the surface
epithelium of the ovaries at a high rate, as also occurs in women
[6]. Thus, the laying hen is a unique animal model for human
EOC research aimed at development of a biomarker(s) for
detection and early diagnosis, as well as for discovery of anti-
cancer drugs/biomaterials for prevention and treatment of this
deadly disease.
The cell cycle in most eukaryotic cells includes a series of
coordinated events consisting of cell growth, replication of genetic
material, segregation of the duplicated chromosomes and cell
division [7]. In general, the cell division cycle in mammals is
precisely and harmoniously regulated in a timely manner by
different active heterodimeric complexes that include cyclin
dependent kinases (CDKs) and their cognate cyclin partners, as
well as CDK inhibitors (CDKIs) [8]. Thus, tumor development
frequently results when there is deregulation of the cell cycle
control system including abnormal regulation of expression of cell
cycle genes [1]. In human cancerous tissues, such as neoplasms,
different families of cell cycle genes and regulators are frequently
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mutated and dysfunctional [8]. Although expression and func-
tional roles of many CDKs, cyclins and CDKIs are well studied in
mammalian species, including humans and mice, little is known
about their expression and regulation in avian species, especially
laying hens.
MicroRNAs (miRNAs) are endogenous non-coding short RNAs
involved in various biological processes that regulate gene
expression via degradation or inhibition of expression of target
mRNAs. The involvement of miRNA-mediated regulatory
mechanisms affecting gene transcription and translation in human
cell cycle progression has been reported [9,10,11]. Indeed,
miRNA-based fine tuning of expression of cell cycle genes is very
important because improper cell cycle control is likely to lead to
initiation and development of proliferative diseases, such as
cancer. Although numerous miRNAs have been indentified in
chickens, the functional aspects of most chicken miRNAs are not
known and reports of miRNA-mediated post-transcriptional
mechanism regulating cell cycle progression in chickens are not
available. Understanding the target spectrum of cell cycle-related
miRNAs and their functional interactions is expected to help
elucidate the molecular and epigenetic regulatory mechanisms
affecting transcriptional and translational events critical to control
of the cell cycle and progression into carcinogenesis. Therefore,
the objectives of this study with laying hens were to determine: 1)
the expression of cyclins, CDKs and CDKIs in normal and
cancerous ovaries; and 2) whether cyclins, CDKs and CDKIs are
regulated by post-transcriptional actions of specific microRNAs
(miRs) using a miR target validation assay. Our results confirm
that the laying hen is a unique model for the research on human
ovarian cancer and cell cycle-related genes and that regulatory
factors for cell cycle-related genes play a key role in ovarian
carcinomas. These cell cycle-related genes may be important
targets for discovery of a biomarker(s) for diagnosis and evaluation
of therapeutics designed to treat EOC in women.
Results
Comparative Expression of Cyclin Genes in Normal and
Cancerous Ovaries from Laying Hens
To determine tissue-specific expression patterns of the cell cycle-
related genes in normal (n = 5) and cancerous (n = 10) ovaries from
laying hens, we performed RT-PCR, and quantitative PCR
analyses. As illustrated in Figure 1, expression of cyclin A2
(CCNA2), CCND1, CCND2, CCND3 and CCNE2 mRNAs was 3.42-
(P,0.01), 1.32- (P,0.05), 2.41- (P,0.01), 3.31- (P,0.05) and
2.36-fold (P,0.001) greater in cancerous ovaries from hens. Next,
cell-specific localization of these genes in the normal and
cancerous ovaries was determined using in situ hybridization
analysis. The mRNAs for CCNA2, CCND1, CCND2, CCND3 and
CCNE2 were localized predominantly to the glandular epithelium
(GE) in cancerous ovaries, but there was very weak or no
detectable expression of these genes in the luminal epithelium
(LE), stromal cells or blood vessels in normal and cancerous
ovaries.
Comparative Expression of Cyclin Dependent Kinase and
Cyclin Dependent Kinase Inhibitor Genes in Normal and
Cancerous Ovaries of Laying Hens
As shown in Figure 2, the results from RT-PCR and
quantitative PCR analyses showed that expression of mRNAs
for cyclin dependent kinase 1 (CDK1), CDK3 and CDK5 were 2.87-
(P,0.01), 5.18- (P,0.01) and 3.66-fold (P,0.01) greater in
cancerous ovaries from hens, respectively. Interestingly, cyclin
dependent kinase inhibitor 1A (CDKN1A) and CDKN1B mRNAs
were 5.62- (P,0.01) and 2.31-fold (P,0.05) more abundant in
cancerous as compared with normal ovaries. In situ hybridization
analyses demonstrated that expression of CDK1, CDK3, CDK5,
CDKN1A and CDKN1B mRNAs was abundant in GE and to
a much lesser extent in stromal cells of cancerous ovaries, whereas
there was very little or no expression of these genes in normal
ovaries.
Post-transcriptional Regulation of Specific Cell Cycle
Regulatory Genes by Chicken microRNAs
A microRNA (miR) target validation assay was used to test the
hypothesis that expression of cell cycle genes is regulated at the
post-transcriptional level by specific miRNAs. Analysis of potential
miRNA binding sites within the 39-UTR of the six cell cycle
regulatory genes was performed using the miRNA target pre-
diction database (miRDB; http://mirdb.org/miRDB/). This
analysis revealed putative binding sites for several chicken
miRNAs (miR-1798 for CCND1; miR-1699 for CCNE2; miR-223
for CDK1; miR-1744 for CDK3; miR-1626 for CDKN1A; and miR-
222, miR-1787 and miR-1812 for CDKN1B), but not for the other
four genes of interest. Therefore, we determined whether these
miRNAs influenced expressions of cell cycle regulatory genes via
the 39-UTR. As illustrated in Figures 3 and 4, in the presence of
miR-1798 and miR-1699, the intensity and percentage of GFP-
CCND1-expressing cells (12.7% in control vs. 4.2% in miR-1798)
and GFP-CCNE2-expressing cells (96.4% in control vs. 71.4% in
miR-1699) decreased (P,0.01). In addition, as shown in Figures 5
and 6, in the presence of miR-223 and miR-1744, the intensity and
percentage of GFP-CDK1-expressing cells (17.2% in control vs.
1.3% in miR-223) and GFP-CDK3-expressing cells (16.1% in
control vs. 6.8% in miR-1744) were decreased (P,0.01).
Moreover, in the presence of miR-1626, the intensity and
percentage of GFP-CDKN1A-expressing cells (54.6% in control
vs. 34.7% in miR-1626) were decreased (P,0.01) (Figure 7). In
addition, for CDKN1B, in the presence of miR-222, miR-1787 and
miR-1812, the intensity and percentage of GFP-CDKN1B-
expressing cells (29.0% in control vs. 15.6% in miR-1787, 12.6%
in miR-1812, 9.8% in miR-222) were decreased (P,0.01) (Figure 8).
These results indicate that at least one to three miRNAs bind
directly to the cell cycle-related gene transcripts to regulate
expression.
Discussion
Results of the present study provide the first evidence of
significant differences in expression of CCNA2, CCND1, CCND2,
CCND3, CCNE2, CDK1, CDK 3, CDK5, CDKN1A and CDKN1B
genes in cancerous as compared to normal ovaries of laying hens.
In addition, our results indicate that several microRNAs (miRs),
specifically miR-222, miR-223, miR-1626, miR-1699, miR-1744,
miR-1787, miR-1798 and miR-1812 interact with sites in the 39-
UTR of the cell cycle genes and regulatory factors affecting cell
cycle genes including CCND1, CCNE2, CDK1, CDK3, CDKN1A and
CDKN1B to influence post-transcriptional regulation of its
expression in laying hens. These results support our hypothesis
that cell cycle genes are critical regulators for growth and
developmental aspects of epithelial cells of the ovaries of hens
and that there is dysregulation of their level of expression as
ovaries of laying hens transition from a normal to a cancerous
state.
In the United States, ovarian cancer is the most common
malignancy in the female genital tract and the fifth leading cause
of cancer-related deaths among women. The surface epithelial-
derived ovarian cancer (EOC) accounts for 90% of all ovarian
Cell Cycle Genes in the Chicken Ovarian Cancer
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cancers [12]. The idea that the repeated rupture of the ovarian
surface epithelium during the monthly ovulation event in women
may contribute to or accelerate the incidence of the EOC was
proposed by Fathalla about four decades ago [13]; however, the
etiology and pathology of the EOC is complicated and not fully
understood. Results of a number of epidemiological and histolog-
ical studies strongly support the idea that there is an increased
incidence of EOC dependent on the frequency of ovulation and
other factors associated with the reproductive tract [14]. However,
there is evidence suggesting that serous-type carcinomas do not
begin as precursor lesions in the fimbria of the fallopian tube in
women and then spread to the surface epithelium of the ovary or
shed into the peritoneal cavity [15,16,17]. In addition, there is
a report indicating that EOC is caused from instability of the copy
number of a certain gene, but not from the mutation of the gene(s)
[18]. At present, the laying hen is an established animal model for
study of EOC to elucidate the pathogenesis and etiologies of EOC
because they spontaneously develop surface epithelium-derived
Figure 1. Comparative expression patterns for CCNA2, CCND1, CCND2, CCND3 and CCNE2 mRNAs in normal and cancerous ovaries
from laying hens. RT-PCR and quantitative RT-PCR analysis were conducted using cDNA templates from normal and cancerous ovaries of laying
hens using chicken CCNA2, CCND1, CCND2, CCND3 and CCNE2 and chicken GAPDH specific primers (left panel). These experiments were conducted in
triplicate and values normalized to those for GAPDH. In situ hybridization analysis indicates cell specific expression patterns for CCNA2, CCND1,
CCND2, CCND3 and CCNE2 mRNAs in both normal and cancerous ovaries from laying hens (right panel). See Materials and Methods for complete
description.
doi:10.1371/journal.pone.0051592.g001
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ovarian cancer at a high rate as occurs in women [6]. There are no
reports that ovarian carcinoma has its origin in the oviduct
(fallopian tube) of laying hens. Further, except for serous
carcinoma, there are no reports of the other three types of
ovarian cancer including endometrioid, mucinous and clear cell
carcinomas in humans. Therefore, future studies will investigate
the origins of the different types of ovarian carcinoma are
regulatory mechanism(s) that govern the initiation and develop-
ment of ovarian carcinogenesis in women and laying hen.
Cyclins are a family of proteins that control the cell cycle by
binding and activating cyclin-dependent kinases. As illustrated in
Figures 1, D-type cyclins, which are G1 phase regulators of the cell
cycle [1,8], such as CCND1, CCND2 and CCND3 are pre-
dominantly found in cancerous ovaries, but there was weak or little
expression in normal ovaries of laying hens in the present study. In
humans, CCND1 is frequently overexpressed in a variety of tumor
types and is associated with carcinogenesis and metastasis [19].
Dhar and colleagues reported that expression of CCND1 was up-
regulated in about 90% of patients with EOC and expressed
mainly in both borderline and invasive tumours without any
association between immunoreactive protein overexpression and
stage of tumor differentiation or grade of tumor [20]. In the
Figure 2. Comparative expression patterns for CDK1, CDK3, CDK5, CDKN1A and CDKN1BmRNAs in normal and cancerous ovaries from
laying hens. RT-PCR and quantitative RT-PCR analyses were conducted using cDNA templates from normal and cancerous ovaries of laying hens
with chicken CDK1, CDK3, CDK5, CDKN1A and CDKN1B and chicken GAPDH specific primers (left panel). These experiments were conducted in
triplicate and normalized to values for GAPDH. In situ hybridization analysis indicates cell specific expression patterns of CDK1, CDK3, CDK5, CDKN1A
and CDKN1B mRNAs both normal and cancerous ovaries from laying hens (right panel). See Materials and Methods for complete description.
doi:10.1371/journal.pone.0051592.g002
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present study, we found CCND1, CCND2 and CCND3 mRNAs in
the nucleus and the cytoplasm of epithelial cells of normal ovaries,
but exclusively in the cytoplamic compartment of the epithelial
cells in cancerous ovaries of laying hens. This result is consistent
with deregulation of CCND1 expression leading to localization of
the protein in both the cytoplasmic and nuclear compartments of
cells from cancerous ovaries [20]. Interestingly, although CCND2
and CCND3 are not overexpressed in human ovarian cancer [21],
messenger RNA expression levels for both CCND2 and CCND3
were significantly upregulated in cancerous ovaries of laying hens.
The difference in expression of these genes between humans and
laying hens should be elucidated. Expression of CCNE2 mRNA,
a G1-S phase regulator [7], in cancerous ovaries from hens was
2.36-fold (P,0.001) greater than in normal ovaries, and mainly
detected in the glandular epithelium (GE). This result supports the
idea that CCNE protein is valuable prognostic factors for EOC
patients because amplification and over-expression of the CCNE1
gene occurs in many cases with a gradual increase from benign to
borderline to malignant tumors [21,22]. In addition, CCNA2
mRNA, an S phase regulators [1,7], was found predominantly in
GE and its expression was 3.42-fold (P,0.01) greater in cancerous
ovaries of laying hens. In humans, CCNA expression increased in
Figure 3. In vitro target assay formicroRNAs on the CCND1 transcript. [A] Diagram of miR-1798 binding sites in the 39-UTR of the CCND1 gene.
[B] Expression vector maps for eGFP within the 39-UTR of the CCND1 gene and Ds-Red within each miRNA. The 39-UTR of the CCND1 transcript was
subcloned between the eGFP gene and the polyA tail to generate the fusion construct of the GFP transcript following the miRNA target 39-UTR
(pcDNA-eGFP-39UTR) (upper panel) and the miRNA expression vector was designed to co-express DsRed and each miRNA (pcDNA-DsRed-miRNA)
(lower panel). [C and D] After co-transfection of pcDNA-eGFP-39UTR for the CCND1 transcript and pcDNA-DsRed-miRNA for miR-1798, the
fluorescence signals of GFP and DsRed were detected using FACS [C] and fluorescent microscopy [D]. See Materials and Methods for complete
description.
doi:10.1371/journal.pone.0051592.g003
Figure 4. In vitro target assay for microRNAs on the CCNE2 transcript. [A] Diagram of miR-1699 binding sites in the 39-UTR of the CCNE2 gene.
[B] Expression vector maps for eGFP within the 39-UTR of the CCNE2 gene and Ds-Red within each miRNA. The 39-UTR of the CCNE2 transcript was
subcloned between the eGFP gene and the polyA tail to generate the fusion construct of the GFP transcript following the miRNA target 39-UTR
(pcDNA-eGFP-39UTR) (upper panel) and the miRNA expression vector was designed to co-express DsRed and each miRNA (pcDNA-DsRed-miRNA)
(lower panel). [C and D] After co-transfection of pcDNA-eGFP-39UTR for the CCNE2 transcript and pcDNA-DsRed-miRNA for the miR-1699, the
fluorescence signals of GFP and DsRed were detected using FACS [C] and fluorescent microscopy [D]. See Materials and Methods for complete
description.
doi:10.1371/journal.pone.0051592.g004
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the ovarian carcinoma cell line compared with normal cells [23]
and CCNA protein was detected mainly in serous and endome-
trioid carcinomas, but not in mucinous and clear cell carcinomas
[24].
Cyclin dependent kinases (CDKs) are the catalytic subunits of
a large family of heterodimeric serine/threonine protein kinases
that have essential roles in controlling progression of the cell cycle
[25]. In the present study, we found that CDK1, CDK3 and CDK5
mRNAs were up-regulated predominantly in GE of cancerous
ovaries, but there was weak or no expression of these mRNAs in
normal ovaries of laying hens. In general, CDK1 has an essential
role in the transition of cells into mitosis under normal
circumstances as a component of the cell cycle control system
and it is also involved in rapid arrest in G2 phase in response to
DNA damage [26]. Overexpression of CDK1 is detected in 79%
of EOC patients, but not in benign epithelial tumors or normal
epithelial tissues in women [27]. In addition, overexpression of
CDK2 was found in only 6% of EOC patients, but its level of
expression was positively correlated with CCNE abundance,
suggesting that overexpression of both CDK2 and CCNE is
significantly associated with development of malignant ovarian
tumors [22,28]. Furthermore, CDK4 is overexpressed in 14% to
Figure 5. In vitro target assay for microRNAs on the CDK1 transcript. [A] Diagram of miR-223 binding sites in the 39-UTR of the CDK1gene. [B]
Expression vector maps for eGFP within the 39-UTR of the CDK1 gene and Ds-Red within each miRNA. The 39-UTR of the CDK1 transcript was
subcloned between the eGFP gene and the polyA tail to generate the fusion construct for the GFP transcript following the miRNA target 39-UTR
(pcDNA-eGFP-39UTR) (upper panel) and the miRNA expression vector was designed to co-express DsRed and each miRNA (pcDNA-DsRed-miRNA)
(lower panel). [C and D] After co-transfection of pcDNA-eGFP-39UTR for the CDK1 transcript and pcDNA-DsRed-miRNA for the miR-223, the
fluorescence signals of GFP and DsRed were detected using FACS [C] and fluorescent microscopy [D]. See Materials and Methods for complete
description.
doi:10.1371/journal.pone.0051592.g005
Figure 6. In vitro target assay for microRNAs on the CDK3 transcript. [A] Diagram of miR-1744 binding sites in the 39-UTR of the CDK3gene. [B]
Expression vector maps for eGFP within the 39-UTR of the CDK3 gene and Ds-Red within each miRNA. The 39-UTR of the CDK3 transcript was
subcloned between the eGFP gene and the polyA tail to generate the fusion construct for the GFP transcript following the miRNA target 39-UTR
(pcDNA-eGFP-39UTR) (upper panel) and the miRNA expression vector was designed to co-express DsRed and each miRNA (pcDNA-DsRed-miRNA)
(lower panel). [C and D] After co-transfection of pcDNA-eGFP-39UTR for the CDK3 transcript and pcDNA-DsRed-miRNA for the miR-1744, the
fluorescence signals of GFP and DsRed were detected using FACS [C] and fluorescent microscopy [D]. See Materials and Methods for complete
description.
doi:10.1371/journal.pone.0051592.g006
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15% of ovarian tumors [29] and its activity in malignant ovarian
tumors is significantly greater than in benign tumors [22]. These
results suggest that CDK4 activity play important roles in ovarian
carcinogenesis. Collectively, results of the present study strongly
Figure 7. In vitro target assay formicroRNAs in the CDKN1A transcript. [A] Diagram ofmiR-1626 binding sites in 39-UTR of the CDKN1A gene. [B]
Expression vector maps for eGFP within the 39-UTR of the CDKN1A gene and Ds-Red within each miRNA. The 39-UTR of the CDKN1A transcript was
subcloned between the eGFP gene and the polyA tail to generate the fusion construct of the GFP transcript following the miRNA target 39-UTR
(pcDNA-eGFP-39UTR) (upper panel) and the miRNA expression vector was designed to co-express DsRed and each miRNA (pcDNA-DsRed-miRNA)
(lower panel). [C and D] After co-transfection of pcDNA-eGFP-39UTR for the CDKN1A transcript and pcDNA-DsRed-miRNA for the miR-1626, the
fluorescence signals of GFP and DsRed were detected using FACS [C] and fluorescent microscopy [D]. See Materials and Methods for complete
description.
doi:10.1371/journal.pone.0051592.g007
Figure 8. In vitro target assay for microRNAs in the CDKN1B transcript. [A] Diagram of miR-222, miR-1787 and miR-1812 binding sites in the 39-
UTR of the CDKN1Bgene. [B] Expression vector maps for eGFP within the 39-UTR of the CDKN1B gene and Ds-Red within each miRNA. The 39-UTR of
the CDKN1B transcript was subcloned between the eGFP gene and the polyA tail to generate the fusion construct of the GFP transcript following the
miRNA target 39-UTR (pcDNA-eGFP-39UTR) (upper panel) and the miRNA expression vector was designed to co-express DsRed and each miRNA
(pcDNA-DsRed-miRNA) (lower panel). [C and D] After co-transfection of pcDNA-eGFP-39UTR for the CDKN1B transcript and pcDNA-DsRed-miRNA for
the miR-222, miR-1787 and miR-1812, the fluorescence signals of GFP and DsRed were detected using FACS [C] and fluorescent microscopy [D]. See
Materials and Methods for complete description.
doi:10.1371/journal.pone.0051592.g008
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indicate that CDK activity is regulated by cyclin synthesis and
degradation, and that orderly progression through the cell cycle
requires coordinated activation of the CDK proteins by binding to
the cyclin partner [8]. Furthermore, the results confirm that the
laying hen is an appropriate animal model for identifying and
developing biomarkers for early diagnosis and evaluation of
therapeutics for treatment of ovarian cancer
[5,6,30,31,32,33,34,35,36].
MicroRNAs, short and noncoding RNAs of 18 to 23 nucleotides
in length, regulate complex patterns of gene expression post-
transcriptionally and are capable of defining and altering cell fate
by silencing translational of gene transcripts through cleavage of
their target mRNAs through base pairing at partially or fully
complementary sites [37]. As shown in Figures 3, 4, 5, 6, miR-1798
and miR-1699 influence the expression of CCND1 and CCNE2,
respectively, while miR-223 and miR-1744 regulate expression of
CDK1 and CDK3, respectively. By regulating post-transcriptional
events, miRs affect function of a number of cellular processes in
development, differentiation and oncogenesis [38,39,40]. Results
of the present study demonstrated that miR-1798 inhibits
expression of CCND1 in laying hens. In human ovarian cancer,
deregulation of CCND1 expression mainly occurs without any
gene amplification [20]. Thus, we suggest dysfunction of miR-1787
leads to the overexpression of CCND1 in cancerous ovaries of
laying hens. In fact, deregulation of miRs is generally considered
to be a prerequisite for initiation and progression of carcinogenesis
in humans. For instance, functional overexpression of miR-31
inhibits proliferation and induces apoptosis in a variety of serous-
type ovarian cancer cell lines, such as SKOV3, with a dysfunc-
tional p53 pathway [41]. In addition, miR expression of
transcriptional targets of p53 (i.e. miR-34b and miR-34c) is
markedly down-regulated in human EOC tissues [42]. These
results indicated that miRs may be useful in predicting outcomes
of many diverse carcinomas, including EOC.
As shown in Figure 2, there is overexpression of cyclin
dependent kinase inhibitor 1A (CDKN1A) and CDKN1B mRNAs
in cancerous ovaries of laying hens. CDKN1A and CDKN1B (also
known as p21/WAF1 and p27, respectively) are potent CDK
inhibitors and act as regulators in the G1 phase of the cell cycle. In
humans, aberrant expression of CDKN1A and/or CDKN1B in
various carcinomas of lung, colorectum, cervix, head and neck
leads to carcinogenesis by blocking DNA synthesis and inhibiting
cell growth [43,44,45,46]. In other words, loss of both genes may
contribute to tumor progression. For instance, loss of CDKN1B
protein was significantly associated with a relatively shorter time to
cell cycle progression and decreased overall survival rates in
patients with advanced ovarian cancer [47]. These results indicate
that both CDKN1A and CDKN1B are potential prognostic
markers to predict progression of EOC and survival in EOC
patients. However, it has been reported that CDKN1B has dual
functional roles during tumorigenesis. In mice, Cdkn1b acts as
a tumor suppressor due to its cyclin-CDK regulatory function and
it acts as an oncogene through a cyclin-CDK-independent
function [48]. These results may explain why CDKN1A and
CDKN1B genes have controversial patterns of expression pattern in
human and mouse tumors. Therefore, we suggest that synchro-
nous up-regulation of CDKN1A and CDKN1B genes with other
CDK genes in the present study may be caused by a CDK-
independent-oncogenic-function of both CDKN1A and CDKN1B
instead of an inhibitory function of these CDKs [48]. Future
research is required to gain a better understanding of the CDK-
independent-oncogenic-function of both genes in ovarian carci-
nogenesis in laying hens. In addition, our miR target validation
assay demonstrated that miR-1626 regulates CDKN1A expression
and miR-222, miR-1787 and miR-1812 influence post-transcrip-
tional modification of transcripts of the CDKN1B gene. These
results suggest that down-regulation of these miRs might
contribute to the overexpression of cell cycle genes and regulatory
factors in chicken ovarian cancer and to transcriptional de-
regulation of many genes in the genome, that may lead to
uncontrolled carcinogenesis.
Collectively, results of the present study indicate that over-
expression of cell cycle-related genes (i.e. cyclins, their associated
kinases and inhibitors) may be involved in uncontrolled cell
proliferation, growth and loss of function in cells that leads to
ovarian tumorigenesis in laying hens. Furthermore, post-transcrip-
tional regulation of the specific miRs that influence expression of
cell cycle genes likely leads to an alternative mechanism(s) for
regulation of their expression. Although results of this study
indicate that various miRs might be involved in many different
oncogenic/carcinogenic pathways, details of altered expression
patterns and their relevance to EOC remain to be elucidated.
Thus, further research is clearly required to unravel the
mechanism(s) for post-transcriptional regulation of cell cycle-
dependent gene expression and different oncogenic pathways
leading to ovarian carcinogenesis in women and in laying hens.
Materials and Methods
Experimental Animals and Animal Care
The experimental use of chickens for this study was approved by
the Institute of Laboratory Animal Resources, Seoul National
University (SNU-070823-5). White Leghorn (WL) laying hens
were subjected to standard management practices at the Seoul
National University Animal Farm, Seoul, Republic of Korea. All
chickens were exposed to a light regimen of 15 h light and 9 h
dark with ad libitum access to feed and water, as well as standard
management practices for feeding and husbandry.
Tissue Samples
In this study, a total of 136 laying hens (88 over 36 months of
age and 48 over 24 months of age), which had completely stopped
laying eggs, were euthanized for biopsy and cancerous (n = 10)
ovaries were collected. As a control, normal (n = 5) ovaries were
also collected from laying hens. We examined tumor stage and the
degree of metastasis in 10 hens with cancerous ovaries according
to characteristic features of chicken epithelial ovarian cancers [5]
(see the Table 1 of the reference). In three hens, ovarian tumor
cells were classified as Stage III as they had metastasized to the
gastrointestinal tract and superficial surface of the liver with
profuse ascites in the abdominal cavity. In five hens, the tumors
had metastasized to distant organs such as liver parenchyma, lung,
gastrointestinal tract and oviduct with profuse ascites, so these
were classified at Stage IV tumors. The other two hens did not
have tumors in any other organs; therefore, their ovarian tumors
were classified as Stage I. The collected cancerous and normal
ovaries containing follicles, glands, stromal cells and blood vessels
were frozen in liquid nitrogen or fixed in 4% paraformaldehyde
for further analyses. Frozen tissue samples were cut into 5- to 7-
mm pieces before being frozen in liquid nitrogen. The other
samples were cut into 10 mm pieces and fixed in 4% para-
formaldehyde in PBS (pH 7.4). After 24 h, fixed tissues were
changed to 70% ethanol for 24 h and then dehydrated and
embedded in Paraplast-Plus (Leica Microsystems, Wetzlar,
Germany). Paraffin-embedded tissues were sectioned at 5 mm
and stained with hematoxylin and eosin. Epithelial ovarian cancers
in laying hens were classified based on their cellular subtypes and
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patterns of cellular differentiation with reference to ovarian
malignant tumor types in humans.
RNA Isolation
Total cellular RNA was isolated from frozen tissues using Trizol
reagent (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s recommendations. The quantity and quality of total RNA
was determined by spectrometry and denaturing agarose gel
electrophoresis, respectively.
Semiquantitative RT-PCR Analysis
The expression of mRNAs for cell cycle genes in normal and
cancerous ovaries of laying hens was assessed using semi-
quantitative RT-PCR as described previously [49]. Information
on the primer sets is provided in Table 1. The cDNA was
synthesized from total cellular RNA (2 ug) using random hexamer
(Invitrogen, Carlsbad, CA) and oligo (dT) primers and AccuPo-
werH RT PreMix (Bioneer, Daejeon, Korea). The cDNA was
diluted (1:10) in sterile water before use in PCR. The primers,
PCR amplification and verification of their sequences were
conducted as described previously [49]. After PCR, equal amounts
of reaction product were analyzed using a 1% agarose gel, and
PCR products were visualized using ethidium bromide staining.
The amount of DNA present was quantified by measuring the
intensity of light emitted from correctly sized bands under
ultraviolet light using a Gel DocTM XR+ system with Image
LabTM software (Bio-Rad).
Quantitative RT-PCR Analysis
Total RNA was extracted from normal and cancerous ovarian
tissue using TRIzol (Invitrogen) and purified using an RNeasy
Mini Kit (Qiagen). Complementary DNA was synthesized using
a SuperscriptH III First-Strand Synthesis System (Invitrogen).
Gene expression levels were measured using SYBRH Green
(Biotium, Hayward, CA, USA) and a StepOnePlusTM Real-Time
PCR System (Applied Biosystems, Foster City, CA, USA). The
glyceraldehydes 3-phosphate dehydrogenase (GAPDH) gene was analyzed
simultaneously as a control and used for normalization of data.
Each target gene and GAPDH were analyzed in triplicate. Using
the standard curve method, we determined the expression
quantities of the examined genes using the standard curves and
Ct values, and normalized them to GAPDH expression values.
ROX dye (Invitrogen) was used as a negative control for the
fluorescence measurements. Sequence-specific products were
identified by generating a melting curve in which the Ct value
represented the cycle number at which a fluorescent signal rose
statistically above background, and relative gene expression was
quantified using the 2–DDCt method [50]. For the control, the
relative quantification of gene expression was normalized to the Ct
of the control ovaries. Information on the primer sets is provided
in Table 2.
In Situ Hybridization Analysis
For hybridization probes, PCR products were generated from
cDNA with the primers used for RT-PCR analysis. The products
were gel-extracted and cloned into pGEM-T vector (Promega).
After verification of the sequences, plasmids containing gene
sequences were amplified with T7- and SP6-specific primers
(T7:59-TGT AAT ACG ACT CAC TAT AGG G-39; SP6:59-
CTA TTT AGG TGA CAC TAT AGA AT-39) then digoxigenin
(DIG)-labeled RNA probes were transcribed using a DIG RNA
labeling kit (Roche Applied Science, Indianapolis, IN). Tissues
were collected and fixed in 4% paraformaldehyde. The tissues
Table 1. Information on primers for RT-PCR analyses.
Gene Sequence (5’R3’): GenBank
Product Size
(bp)
forward and reverse accession no.
CCNA2 ATGTCAGCGATATCCACACG
GCTCCATCCTCAGAACTTGC
NM_205244.1 354
CCND1 AGACCATCCGACGAGCCTAC
GCAGCCAGATTCCATTTCAG
NM_205381.1 430
CCND2 AGTTGCTGTGCTGCGAGGT
GCTCTTGGGGTTTGATGGAA
NM_204213.1 402
CCND3 CGTCTCCTACTTCCAATGCG
GGTCTGTGCGTGCTTCTTCA
NM_001008453.1 430
CCNE2 ACCTCACTCTTCATTGCCTCC
TCACAAACGGAACCATCCAC
NM_001030945.1 427
CDK1 GGCAGATTTTGGATTGGCTC NM_205314.1 431
CGAAGTATGGGTGGTTCAAGG
CDK3 ACCCCAACATCGTCAAACTG
GCGTCACCATCTCAGCAAAA
NM_001081706.2 417
CDK5 TCTGGTCTTTGAGTTCTGCGA
TGGGGTAGGGCTTGTAGTCA
NM_001135786.1 491
CDKN1A CGTGCAGGAACCTCTTCG
TCACAGCTTGGGCTTATCG
NM_204396.1 407
CDKN1B CGCAAGGAAATGGAAGAGG
GTTTGATGTCGTCTCGGGC
NM_204256.2 449
GAPDH TGCCAACCCCCAATGTCTCTGT
TCCTTGGATGCCATGTGGACCA
NM_204305.1 301
doi:10.1371/journal.pone.0051592.t001
Table 2. Information on primers for quantitative PCR
analyses.
Gene Sequence (5’R3’): GenBank
Product Size
(bp)
forward and reverse accession no.
CCNA2 TATTCTGGTGGACTGGCTGG
CGAACTCTGCTACTTCAGGGG
NM_205244.1 200
CCND1 GACTTTTGTGCGTCTGTGCG
TCTTGGCAGGCTCGTAAACT
NM_205381.1 198
CCND2 CAAGCACAGATGTGGACTGC
CTGGTCCAGTTCCTCAATGG
NM_204213.1 131
CCND3 GATGGAGCTGGTGAAGAAGC
GCTTCAGGCTCTCAGCTAGG
NM_001008453.1 254
CCNE2 GCTGCACTCTGCCACTATACC
ATTCACAAACGGAACCATCC
NM_001030945.1 105
CDK1 AGGTATCGTCTTCTGCCATTCA NM_205314.1 110
GAGCCAATCCAAAATCTGCC
CDK3 CCAGAAGGTGGAGAAGATCG
GCCTGACTATGTTGGGATGC
NM_001081706.2 185
CDK5 CGAGAAGCTGGAGAAGATCG
CCAGAGTCAGCTTCTTGTCG
NM_001135786.1 224
CDKN1A GTGTCGGTGGGGCTCATC
GCTTGGCGTTATCGTGGAC
NM_204396.1 144
CDKN1B AAGAAGCACCGCAAGGAAAT
CTGCCTGAAGTAGAAGTCGGG
NM_204256.2 138
GAPDH ACACAGAAGACGGTGGATGG
GGCAGGTCAGGTCAACAACA
NM_204305.1 193
doi:10.1371/journal.pone.0051592.t002
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were embedded in paraffin and sectioned at 5 mm on APES-
treated (silanized) slides. The sections were then deparaffinized in
xylene and rehydrated to diethylpyrocarbonate (DEPC)-treated
water through a graded series of alcohol. The sections were treated
with 1% Triton X-100 in PBS for 20 min and washed two times in
DEPC-treated PBS. After washing in DEPC-treated PBS, the
sections were digested in TE buffer (100 mMTris-HCl, 50 mM
EDTA, pH 8.0) containing 5 mg/ml Proteinase K (Sigma
Chemical Co., St. Louis, MO) at 37uC. After post-fixation in
4% paraformaldehyde, sections were incubated twice for 5 min
each in DEPC-treated PBS and incubated in TEA buffer (0.1 M
triethanolamine) containing 0.25% (v/v) acetic anhydride. The
sections were incubated in a prehybridization mixture containing
50% formamide and 4X standard saline citrate (SSC) for at least
10 min at room temperature. After prehybridization, the sections
were incubated with a hybridization mixture containing 40%
formamide, 4X SSC, 10% dextran sulfate sodium salt, 10 mM
DTT, 1 mg/ml yeast tRNA, 1 mg/ml salmon sperm DNA,
0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.2 mg/ml RNase-free
bovine serum albumin and denatured DIG-labeled cRNA probe
overnight at 42uC in a humidified chamber. After hybridization,
sections were washed for 15 min in 2X SSC at 37uC, 15 min in
1X SSC at 37uC, 30 min in NTE buffer (10 mM Tris, 500 mM
NaCl and 1 mM EDTA) at 37uC and 30 min in 0.1X SSC at
37uC. After blocking with a 2% normal sheep serum (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), the sections were incubated
overnight with sheep anti-DIG antibody conjugated to alkaline
phosphatase (Roche, Indianapolis, IN). The signal was visualized
by exposure to a solution containing 0.4 mM 5-bromo-4-chloro-3-
indolylphosphate, 0.4 mM nitrobluetetrazolium, and 2 mM
levamisole (Sigma Chemical Co., St. Louis, MO).
MicroRNA Target Validation Assay
The 39-UTR of selected genes was cloned and confirmed by
sequencing. The 39-UTR was subcloned between the eGFP gene
and the bovine growth hormone (bGH) poly-A tail in
pcDNA3eGFP (Clontech, Mountain View, CA) to generate the
eGFP-miRNA target 39-UTR (pcDNA-eGFP-39UTR) fusion
constructs. For the dual fluorescence reporter assay, the fusion
constructs containing the DsRed gene and each microRNA were
designed to be co-expressed under control of the CMV promoter
(pcDNA-DsRed-miRNA). The pcDNA-eGFP-39UTR and
pcDNA-DsRed-miRNA (4 mg) were co-transfected into 293FT
cells using the calcium phosphate method. When the DsRed-
miRNA is expressed and binds to the target site of the 39-UTR
downstream of the GFP transcript, green fluorescence intensity
decreases due to degradation of the GFP transcript. At 48 h post-
transfection, dual fluorescence was detected by fluorescence
microscopy and calculated by FACSCalibur flow cytometry (BD
Biosciences). For flow cytometry, the cells were fixed in 4%
paraformaldehyde and analyzed using FlowJo software (Tree Star
Inc., Ashland, OR). We captured fluorescence images using
a confocal laser scanning microscope and zen 2009 microscopy
software (Carl zeiss, Germany) with the following settings: Lenses,
206; Frame size, 128(X) and 128(Y); Laser settings, 3% FITC at
488 nm) and 2.8% DsRed at 555 nm; Scan time, 491 msec;
Pinhole size; 1Airy unit.
Statistical Analyses
Data for quantitative PCR were subjected to analysis of
variance (ANOVA) according to the general linear model
(PROC-GLM) of the SAS program (SAS Institute, Cary, NC).
Data are presented as mean 6 SEM unless otherwise stated.
Differences in the variance between normal and each classification
of cancerous ovary group were analyzed using the F test, and
differences in the means were subjected to Student’s t test.
Differences were considered significant at P,0.05.
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